APO Research
Talk to an analyst

APO RESEARCH · REPORT

Neurodegenerative Drugs

Compare research editions
View pricing & licenses

Selected research

Industry Growth & Trends

Global Neurodegenerative Drugs Industry Growth and Trends Forecast to 2032

19 December 2025114 pages

Choose your research edition.

Industry ResearchNeurodegenerative Drugs Industry Research Report 2026137 pages · $2,950 USDIndustry Growth & TrendsGlobal Neurodegenerative Drugs Industry Growth and Trends Forecast to 2032114 pages · $3,450 USDMarket StructureGlobal Neurodegenerative Drugs Market by Size, by Type, by Application, by Region, History and Forecast 2021-2032190 pages · $3,950 USDMarket Outlook & Growth OpportunitiesGlobal Neurodegenerative Drugs Market Outlook and Growth Opportunities 2026207 pages · $4,250 USDMarket Analysis & ForecastGlobal Neurodegenerative Drugs Market Analysis and Forecast 2026-2032203 pages · $4,950 USD

Market perspective

The global Neurodegenerative Drugs market was valued at US$ million in 2026 and is projected to reach US$ million by 2032, implying a CAGR of xx% over 2026-2032.

The North America market for Neurodegenerative Drugs is projected to increase from US$ million in 2026 to US$ million by 2032, corresponding to a CAGR of % over 2026-2032.

The Europe market for Neurodegenerative Drugs is projected to increase from US$ million in 2026 to US$ million by 2032, registering a CAGR of % over 2026-2032.

Read the full market overview

The Asia Pacific market for Neurodegenerative Drugs is projected to increase from US$ million in 2026 to US$ million by 2032, at a CAGR of % over 2026-2032.

Leading global manufacturers of Neurodegenerative Drugs include TEVA, Sanofi, Novartis, Luye Pharma, Livzon Pharmaceutical, Kanghong Pharmaceutical, Jingxin Pharmaceutical, Pfizer and Huahai Pharmaceutical, among others. In 2025, the top three vendors together accounted for approximately % of global revenue.

Report Scope

This report provides a structured, data-driven view of the global Neurodegenerative Drugs market, combining harmonized quantitative metrics with targeted qualitative insight to support business and growth strategy, market positioning, and capital allocation.

The Neurodegenerative Drugs market size, estimates, and forecasts are presented in terms of sales volume (Tons) and revenue (US$ million), with 2025 as the base year and historical and forecast data for 2021-2032. The report segments the global Neurodegenerative Drugs market by Type, Application, region/country, and company, provides regional market sizes at the segment level, profiles the competitive landscape and key players and their market ranks, and reviews technology trends and new product developments relevant to Neurodegenerative Drugs.

Key Companies & Market Share Insights

This section analyzes the strategies and performance of leading manufacturers in the global Neurodegenerative Drugs market, including portfolio focus, innovation and product development, mergers and acquisitions, collaborations, and geographic expansion used to sustain or enhance competitive positions. It also summarizes recent corporate developments and key financial indicators and provides global revenue, price, and sales volume data by manufacturer for 2020-2025, enabling benchmarking of scale, pricing, and market share and supporting assessment of market concentration through indicators such as CR5 and CR10.

Neurodegenerative Drugs Market by Company

TEVA

Sanofi

Novartis

Luye Pharma

Livzon Pharmaceutical

Kanghong Pharmaceutical

Jingxin Pharmaceutical

Pfizer

Huahai Pharmaceutical

Hisun Pharmaceutical

Haisco Pharmaceutical

GlaxoSmithKline

Ark Pharmaceutical

Dongcheng Biochemicals

BORA PHARMACEUTICALS

UCB

Merck Serono

Boehringer Ingelheim

Biogen Idec

Neurodegenerative Drugs Segment by Type

NMDA

SSRIs

Dopamine Inhibitors

Neurodegenerative Drugs Segment by Application

Parkinson’s Disease

Amyotrophic Lateral Sclerosis

Huntington Disease

Alzheimer’s Disease

Neurodegenerative Drugs Segment by Region

North America

United States

Canada

Europe

Germany

France

U.K.

Italy

Netherlands

Nordic Countries

Asia-Pacific

China

Japan

South Korea

India

Australia

China Taiwan

Southeast Asia

South America

Mexico

Brazil

Argentina

Colombia

Middle East & Africa

Turkey

Saudi Arabia

UAE

Key Drivers & Barriers

High-impact rendering factors and drivers have been studied in this report to aid the readers to understand the general development. Moreover, the report includes restraints and challenges that may act as stumbling blocks on the way of the players. This will assist the users to be attentive and make informed decisions related to business. Specialists have also laid their focus on the upcoming business prospects.

Reasons to Buy This Report

1. This report will help the readers to understand the competition within the industries and strategies for the competitive environment to enhance the potential profit. The report also focuses on the competitive landscape of the global Neurodegenerative Drugs market, and introduces in detail the market share, industry ranking, competitor ecosystem, market performance, new product development, operation situation, expansion, and acquisition. etc. of the main players, which helps the readers to identify the main competitors and deeply understand the competition pattern of the market.

2. This report will help stakeholders to understand the global industry status and trends of Neurodegenerative Drugs and provides them with information on key market drivers, restraints, challenges, and opportunities.

3. This report will help stakeholders to understand competitors better and gain more insights to strengthen their position in their businesses. The competitive landscape section includes the market share and rank (in volume and value), competitor ecosystem, new product development, expansion, and acquisition.

4. This report stays updated with novel technology integration, features, and the latest developments in the market.

5. This report helps stakeholders to gain insights into which regions to target globally.

6. This report helps stakeholders to gain insights into the end-user perception concerning the adoption of Neurodegenerative Drugs.

7. This report helps stakeholders to identify some of the key players in the market and understand their valuable contribution.

Chapter Outline

Chapter 1: Introduces the study scope of this report, executive summary of market segments by type, market size segments for North America, Europe, Asia Pacific, South America, Middle East & Africa.

Chapter 2: Introduces the market dynamics, latest developments of the market, the driving factors and restrictive factors of the market, the challenges and risks faced by manufacturers in the industry, and the analysis of relevant policies in the industry.

Chapter 3: Detailed analysis of Neurodegenerative Drugs manufacturers competitive landscape, price, sales, revenue, market share and ranking, latest development plan, merger, and acquisition information, etc.

Chapter 4: Sales, revenue of Neurodegenerative Drugs in regional level. It provides a quantitative analysis of the market size and development potential of each region and introduces the future development prospects, and market space in the world.

Chapter 5: Introduces market segments by application, market size segment for North America, Europe, Asia Pacific, South America, Middle East & Africa.

Chapter 6: Provides profiles of key players, introducing the basic situation of the main companies in the market in detail, including product sales, revenue, price, gross margin, product introduction, recent development, etc.

Chapter 7, 8, 9, 10 and 11: North America, Europe, Asia Pacific, South America, Middle East & Africa, sales and revenue by country.

Chapter 12: Analysis of industrial chain, key raw materials, manufacturing cost, and market dynamics.

Chapter 13: Concluding Insights of the report.

More report detail

Tables and figures
List of Tables Table 1. Major Company of NMDA Table 2. Major Company of SSRIs Table 3. Major Company of Dopamine Inhibitors Table 4. Global Neurodegenerative Drugs Sales by Type (2021 VS 2025 VS 2032) & (US$ Million) Table 5. Global Neurodegenerative Drugs Sales by Type (2021-2026) & (Tons) Table 6. Global Neurodegenerative Drugs Sales Market Share in Volume by Type (2021-2026) Table 7. Global Neurodegenerative Drugs Sales by Type (2021-2026) & (US$ Million) Table 8. Global Neurodegenerative Drugs Sales Market Share in Value by Type (2021-2026) Table 9. Global Neurodegenerative Drugs Price by Type (2021-2026) & (US$/Ton) Table 10. Global Neurodegenerative Drugs Sales by Type (2027-2032) & (Tons) Table 11. Global Neurodegenerative Drugs Sales Market Share in Volume by Type (2027-2032) Table 12. Global Neurodegenerative Drugs Sales by Type (2027-2032) & (US$ Million) Table 13. Global Neurodegenerative Drugs Sales Market Share in Value by Type (2027-2032) Table 14. Global Neurodegenerative Drugs Price by Type (2027-2032) & (US$/Ton) Table 15. North America Neurodegenerative Drugs Sales by Type (2021-2026) & (Tons) Table 16. North America Neurodegenerative Drugs Sales by Type (2021-2026) & (US$ Million) Table 17. Europe Neurodegenerative Drugs Sales by Type (2021-2026) & (Tons) Table 18. Europe Neurodegenerative Drugs Sales by Type (2021-2026) & (US$ Million) Table 19. Asia-Pacific Neurodegenerative Drugs Sales by Type (2021-2026) & (Tons) Table 20. Asia-Pacific Neurodegenerative Drugs Sales by Type (2021-2026) & (US$ Million) Table 21. Latin America Neurodegenerative Drugs Sales by Type (2021-2026) & (Tons) Table 22. Latin America Neurodegenerative Drugs Sales by Type (2021-2026) & (US$ Million) Table 23. Middle East and Africa Neurodegenerative Drugs Sales by Type (2021-2026) & (Tons) Table 24. Middle East and Africa Neurodegenerative Drugs Sales by Type (2021-2026) & (US$ Million) Table 25. Neurodegenerative Drugs Industry Trends Table 26. Neurodegenerative Drugs Industry Drivers Table 27. Neurodegenerative Drugs Industry Opportunities and Challenges Table 28. Neurodegenerative Drugs Industry Restraints Table 29. Global Neurodegenerative Drugs Sales Revenue by Company (US$ Million) & (2021-2026) Table 30. Global Neurodegenerative Drugs Revenue Market Share by Company (2021-2026) Table 31. Global Neurodegenerative Drugs Sales by Company (2021-2026) & (Tons) Table 32. Global Neurodegenerative Drugs Sales Share by Company (2021-2026) Table 33. Global Neurodegenerative Drugs Market Price by Company (2021-2026) & (US$/Ton) Table 34. Global Neurodegenerative Drugs Industry Company Ranking, 2024 VS 2025 VS 2026 Table 35. Global Neurodegenerative Drugs Major Company Production Sites and Headquarters Table 36. Global Neurodegenerative Drugs Company, Product Type & Application Table 37. Global Neurodegenerative Drugs Company Establishment Date Table 38. Global Company Market Concentration Ratio (CR5 and HHI) Table 39. Global Neurodegenerative Drugs by Company Type (Tier 1, Tier 2, and Tier 3) & (Based on the Revenue of 2025) Table 40. Global Neurodegenerative Drugs Market Size Comparison by Region (US$ Million): 2021 VS 2025 VS 2032 Table 41. Global Neurodegenerative Drugs Sales by Region (2021-2026) & (Tons) Table 42. Global Neurodegenerative Drugs Sales Market Share in Volume by Region (2021-2026) Table 43. Global Neurodegenerative Drugs Sales by Region (2021-2026) & (US$ Million) Table 44. Global Neurodegenerative Drugs Sales Market Share in Value by Region (2021-2026) Table 45. Global Neurodegenerative Drugs Sales (Tons), Value (US$ Million), Price (US$/Ton) and Gross Margin (2021-2026) Table 46. Global Neurodegenerative Drugs Sales by Region (2027-2032) & (Tons) Table 47. Global Neurodegenerative Drugs Sales Market Share in Volume by Region (2027-2032) Table 48. Global Neurodegenerative Drugs Sales by Region (2027-2032) & (US$ Million) Table 49. Global Neurodegenerative Drugs Sales Market Share in Value by Region (2027-2032) Table 50. Global Neurodegenerative Drugs Sales (Tons), Value (US$ Million), Price (US$/Ton) and Gross Margin (2027-2032) Table 51. Global Neurodegenerative Drugs Sales by Application (2021 VS 2025 VS 2032) & (US$ Million) Table 52. Global Neurodegenerative Drugs Sales by Application (2021-2026) & (Tons) Table 53. Global Neurodegenerative Drugs Sales Market Share in Volume by Application (2021-2026) Table 54. Global Neurodegenerative Drugs Sales by Application (2021-2026) & (US$ Million) Table 55. Global Neurodegenerative Drugs Sales Market Share in Value by Application (2021-2026) Table 56. Global Neurodegenerative Drugs Price by Application (2021-2026) & (US$/Ton) Table 57. Global Neurodegenerative Drugs Sales by Application (2027-2032) & (Tons) Table 58. Global Neurodegenerative Drugs Sales Market Share in Volume by Application (2027-2032) Table 59. Global Neurodegenerative Drugs Sales by Application (2027-2032) & (US$ Million) Table 60. Global Neurodegenerative Drugs Sales Market Share in Value by Application (2027-2032) Table 61. Global Neurodegenerative Drugs Price by Application (2027-2032) & (US$/Ton) Table 62. North America Neurodegenerative Drugs Sales by Application (2021-2026) & (Tons) Table 63. North America Neurodegenerative Drugs Sales by Application (2021-2026) & (US$ Million) Table 64. Europe Neurodegenerative Drugs Sales by Application (2021-2026) & (Tons) Table 65. Europe Neurodegenerative Drugs Sales by Application (2021-2026) & (US$ Million) Table 66. Asia-Pacific Neurodegenerative Drugs Sales by Application (2021-2026) & (Tons) Table 67. Asia-Pacific Neurodegenerative Drugs Sales by Application (2021-2026) & (US$ Million) Table 68. Latin America Neurodegenerative Drugs Sales by Application (2021-2026) & (Tons) Table 69. Latin America Neurodegenerative Drugs Sales by Application (2021-2026) & (US$ Million) Table 70. Middle East and Africa Neurodegenerative Drugs Sales by Application (2021-2026) & (Tons) Table 71. Middle East and Africa Neurodegenerative Drugs Sales by Application (2021-2026) & (US$ Million) Table 72. TEVA Company Information Table 73. TEVA Business Overview Table 74. TEVA Neurodegenerative Drugs Sales (Tons), Revenue (US$ Million), Price (US$/Ton) and Gross Margin (2021-2026) Table 75. TEVA Neurodegenerative Drugs Product Portfolio Table 76. TEVA Recent Development Table 77. Sanofi Company Information Table 78. Sanofi Business Overview Table 79. Sanofi Neurodegenerative Drugs Sales (Tons), Revenue (US$ Million), Price (US$/Ton) and Gross Margin (2021-2026) Table 80. Sanofi Neurodegenerative Drugs Product Portfolio Table 81. Sanofi Recent Development Table 82. Novartis Company Information Table 83. Novartis Business Overview Table 84. Novartis Neurodegenerative Drugs Sales (Tons), Revenue (US$ Million), Price (US$/Ton) and Gross Margin (2021-2026) Table 85. Novartis Neurodegenerative Drugs Product Portfolio Table 86. Novartis Recent Development Table 87. Luye Pharma Company Information Table 88. Luye Pharma Business Overview Table 89. Luye Pharma Neurodegenerative Drugs Sales (Tons), Revenue (US$ Million), Price (US$/Ton) and Gross Margin (2021-2026) Table 90. Luye Pharma Neurodegenerative Drugs Product Portfolio Table 91. Luye Pharma Recent Development Table 92. Livzon Pharmaceutical Company Information Table 93. Livzon Pharmaceutical Business Overview Table 94. Livzon Pharmaceutical Neurodegenerative Drugs Sales (Tons), Revenue (US$ Million), Price (US$/Ton) and Gross Margin (2021-2026) Table 95. Livzon Pharmaceutical Neurodegenerative Drugs Product Portfolio Table 96. Livzon Pharmaceutical Recent Development Table 97. Kanghong Pharmaceutical Company Information Table 98. Kanghong Pharmaceutical Business Overview Table 99. Kanghong Pharmaceutical Neurodegenerative Drugs Sales (Tons), Revenue (US$ Million), Price (US$/Ton) and Gross Margin (2021-2026) Table 100. Kanghong Pharmaceutical Neurodegenerative Drugs Product Portfolio Table 101. Kanghong Pharmaceutical Recent Development Table 102. Jingxin Pharmaceutical Company Information Table 103. Jingxin Pharmaceutical Business Overview Table 104. Jingxin Pharmaceutical Neurodegenerative Drugs Sales (Tons), Revenue (US$ Million), Price (US$/Ton) and Gross Margin (2021-2026) Table 105. Jingxin Pharmaceutical Neurodegenerative Drugs Product Portfolio Table 106. Jingxin Pharmaceutical Recent Development Table 107. Pfizer Company Information Table 108. Pfizer Business Overview Table 109. Pfizer Neurodegenerative Drugs Sales (Tons), Revenue (US$ Million), Price (US$/Ton) and Gross Margin (2021-2026) Table 110. Pfizer Neurodegenerative Drugs Product Portfolio Table 111. Pfizer Recent Development Table 112. Huahai Pharmaceutical Company Information Table 113. Huahai Pharmaceutical Business Overview Table 114. Huahai Pharmaceutical Neurodegenerative Drugs Sales (Tons), Revenue (US$ Million), Price (US$/Ton) and Gross Margin (2021-2026) Table 115. Huahai Pharmaceutical Neurodegenerative Drugs Product Portfolio Table 116. Huahai Pharmaceutical Recent Development Table 117. Hisun Pharmaceutical Company Information Table 118. Hisun Pharmaceutical Business Overview Table 119. Hisun Pharmaceutical Neurodegenerative Drugs Sales (Tons), Revenue (US$ Million), Price (US$/Ton) and Gross Margin (2021-2026) Table 120. Hisun Pharmaceutical Neurodegenerative Drugs Product Portfolio Table 121. Hisun Pharmaceutical Recent Development Table 122. Haisco Pharmaceutical Company Information Table 123. Haisco Pharmaceutical Business Overview Table 124. Haisco Pharmaceutical Neurodegenerative Drugs Sales (Tons), Revenue (US$ Million), Price (US$/Ton) and Gross Margin (2021-2026) Table 125. Haisco Pharmaceutical Neurodegenerative Drugs Product Portfolio Table 126. Haisco Pharmaceutical Recent Development Table 127. GlaxoSmithKline Company Information Table 128. GlaxoSmithKline Business Overview Table 129. GlaxoSmithKline Neurodegenerative Drugs Sales (Tons), Revenue (US$ Million), Price (US$/Ton) and Gross Margin (2021-2026) Table 130. GlaxoSmithKline Neurodegenerative Drugs Product Portfolio Table 131. GlaxoSmithKline Recent Development Table 132. Ark Pharmaceutical Company Information Table 133. Ark Pharmaceutical Business Overview Table 134. Ark Pharmaceutical Neurodegenerative Drugs Sales (Tons), Revenue (US$ Million), Price (US$/Ton) and Gross Margin (2021-2026) Table 135. Ark Pharmaceutical Neurodegenerative Drugs Product Portfolio Table 136. Ark Pharmaceutical Recent Development Table 137. Dongcheng Biochemicals Company Information Table 138. Dongcheng Biochemicals Business Overview Table 139. Dongcheng Biochemicals Neurodegenerative Drugs Sales (Tons), Revenue (US$ Million), Price (US$/Ton) and Gross Margin (2021-2026) Table 140. Dongcheng Biochemicals Neurodegenerative Drugs Product Portfolio Table 141. Dongcheng Biochemicals Recent Development Table 142. BORA PHARMACEUTICALS Company Information Table 143. BORA PHARMACEUTICALS Business Overview Table 144. BORA PHARMACEUTICALS Neurodegenerative Drugs Sales (Tons), Revenue (US$ Million), Price (US$/Ton) and Gross Margin (2021-2026) Table 145. BORA PHARMACEUTICALS Neurodegenerative Drugs Product Portfolio Table 146. BORA PHARMACEUTICALS Recent Development Table 147. UCB Company Information Table 148. UCB Business Overview Table 149. UCB Neurodegenerative Drugs Sales (Tons), Revenue (US$ Million), Price (US$/Ton) and Gross Margin (2021-2026) Table 150. UCB Neurodegenerative Drugs Product Portfolio Table 151. UCB Recent Development Table 152. Merck Serono Company Information Table 153. Merck Serono Business Overview Table 154. Merck Serono Neurodegenerative Drugs Sales (Tons), Revenue (US$ Million), Price (US$/Ton) and Gross Margin (2021-2026) Table 155. Merck Serono Neurodegenerative Drugs Product Portfolio Table 156. Merck Serono Recent Development Table 157. Boehringer Ingelheim Company Information Table 158. Boehringer Ingelheim Business Overview Table 159. Boehringer Ingelheim Neurodegenerative Drugs Sales (Tons), Revenue (US$ Million), Price (US$/Ton) and Gross Margin (2021-2026) Table 160. Boehringer Ingelheim Neurodegenerative Drugs Product Portfolio Table 161. Boehringer Ingelheim Recent Development Table 162. Biogen Idec Company Information Table 163. Biogen Idec Business Overview Table 164. Biogen Idec Neurodegenerative Drugs Sales (Tons), Revenue (US$ Million), Price (US$/Ton) and Gross Margin (2021-2026) Table 165. Biogen Idec Neurodegenerative Drugs Product Portfolio Table 166. Biogen Idec Recent Development Table 167. North America Neurodegenerative Drugs Market Size Growth Rate (CAGR) by Country (Tons): 2021 VS 2025 VS 2032 Table 168. North America Neurodegenerative Drugs Sales by Country (2021-2026) & (Tons) Table 169. North America Neurodegenerative Drugs Sales Market Share by Country (2021-2026) Table 170. North America Neurodegenerative Drugs Sales Forecast by Country (2027-2032) & (Tons) Table 171. North America Neurodegenerative Drugs Sales Market Share Forecast by Country (2027-2032) Table 172. North America Neurodegenerative Drugs Market Size Growth Rate (CAGR) by Country (US$ Million): 2021 VS 2025 VS 2032 Table 173. North America Neurodegenerative Drugs Market Size by Country (2021-2026) & (US$ Million) Table 174. North America Neurodegenerative Drugs Market Share by Country (2021-2026) Table 175. North America Neurodegenerative Drugs Market Size Forecast by Country (2027-2032) & (US$ Million) Table 176. North America Neurodegenerative Drugs Market Share Forecast by Country (2027-2032) Table 177. Europe Neurodegenerative Drugs Market Size Growth Rate (CAGR) by Country (Tons): 2021 VS 2025 VS 2032 Table 178. Europe Neurodegenerative Drugs Sales by Country (2021-2026) & (Tons) Table 179. Europe Neurodegenerative Drugs Sales Market Share by Country (2021-2026) Table 180. Europe Neurodegenerative Drugs Sales Forecast by Country (2027-2032) & (Tons) Table 181. Europe Neurodegenerative Drugs Sales Market Share Forecast by Country (2027-2032) Table 182. Europe Neurodegenerative Drugs Market Size Growth Rate (CAGR) by Country (US$ Million): 2021 VS 2025 VS 2032 Table 183. Europe Neurodegenerative Drugs Market Size by Country (2021-2026) & (US$ Million) Table 184. Europe Neurodegenerative Drugs Market Share by Country (2021-2026) Table 185. Europe Neurodegenerative Drugs Market Size Forecast by Country (2027-2032) & (US$ Million) Table 186. Europe Neurodegenerative Drugs Market Share Forecast by Country (2027-2032) Table 187. Asia-Pacific Neurodegenerative Drugs Market Size Growth Rate (CAGR) by Country (Tons): 2021 VS 2025 VS 2032 Table 188. Asia-Pacific Neurodegenerative Drugs Sales by Country (2021-2026) & (Tons) Table 189. Asia-Pacific Neurodegenerative Drugs Sales Market Share by Country (2021-2026) Table 190. Asia-Pacific Neurodegenerative Drugs Sales Forecast by Country (2027-2032) & (Tons) Table 191. Asia-Pacific Neurodegenerative Drugs Sales Market Share Forecast by Country (2027-2032) Table 192. Asia-Pacific Neurodegenerative Drugs Market Size Growth Rate (CAGR) by Country (US$ Million): 2021 VS 2025 VS 2032 Table 193. Asia-Pacific Neurodegenerative Drugs Market Size by Country (2021-2026) & (US$ Million) Table 194. Asia-Pacific Neurodegenerative Drugs Market Share by Country (2021-2026) Table 195. Asia-Pacific Neurodegenerative Drugs Market Size Forecast by Country (2027-2032) & (US$ Million) Table 196. Asia-Pacific Neurodegenerative Drugs Market Share Forecast by Country (2027-2032) Table 197. Latin America Neurodegenerative Drugs Market Size Growth Rate (CAGR) by Country (Tons): 2021 VS 2025 VS 2032 Table 198. Latin America Neurodegenerative Drugs Sales by Country (2021-2026) & (Tons) Table 199. Latin America Neurodegenerative Drugs Sales Market Share by Country (2021-2026) Table 200. Latin America Neurodegenerative Drugs Sales Forecast by Country (2027-2032) & (Tons) Table 201. Latin America Neurodegenerative Drugs Sales Market Share Forecast by Country (2027-2032) Table 202. Latin America Neurodegenerative Drugs Market Size Growth Rate (CAGR) by Country (US$ Million): 2021 VS 2025 VS 2032 Table 203. Latin America Neurodegenerative Drugs Market Size by Country (2021-2026) & (US$ Million) Table 204. Latin America Neurodegenerative Drugs Market Share by Country (2021-2026) Table 205. Latin America Neurodegenerative Drugs Market Size Forecast by Country (2027-2032) & (US$ Million) Table 206. Latin America Neurodegenerative Drugs Market Share Forecast by Country (2027-2032) Table 207. Middle East and Africa Neurodegenerative Drugs Market Size Growth Rate (CAGR) by Country (Tons): 2021 VS 2025 VS 2032 Table 208. Middle East and Africa Neurodegenerative Drugs Sales by Country (2021-2026) & (Tons) Table 209. Middle East and Africa Neurodegenerative Drugs Sales Market Share by Country (2021-2026) Table 210. Middle East and Africa Neurodegenerative Drugs Sales Forecast by Country (2027-2032) & (Tons) Table 211. Middle East and Africa Neurodegenerative Drugs Sales Market Share Forecast by Country (2027-2032) Table 212. Middle East and Africa Neurodegenerative Drugs Market Size Growth Rate (CAGR) by Country (US$ Million): 2021 VS 2025 VS 2032 Table 213. Middle East and Africa Neurodegenerative Drugs Market Size by Country (2021-2026) & (US$ Million) Table 214. Middle East and Africa Neurodegenerative Drugs Market Share by Country (2021-2026) Table 215. Middle East and Africa Neurodegenerative Drugs Market Size Forecast by Country (2027-2032) & (US$ Million) Table 216. Middle East and Africa Neurodegenerative Drugs Market Share Forecast by Country (2027-2032) Table 217. Key Raw Materials Table 218. Raw Materials Key Suppliers Table 219. Neurodegenerative Drugs Distributors List Table 220. Neurodegenerative Drugs Customers List Table 221. Research Programs/Design for This Report Table 222. Authors List of This Report Table 223. Secondary Sources Table 224. Primary Sources List of Figures Figure 1. Neurodegenerative Drugs Image Figure 2. Global Neurodegenerative Drugs Market Size (US$ Million), 2021 VS 2025 VS 2032 Figure 3. Global Neurodegenerative Drugs Market Size (2021-2032) & (US$ Million) Figure 4. Global Neurodegenerative Drugs Sales (2021-2032) & (Tons) Figure 5. NMDA Image Figure 6. Global NMDA Sales YoY Growth (2021-2032) & (Tons) Figure 7. SSRIs Image Figure 8. Global SSRIs Sales YoY Growth (2021-2032) & (Tons) Figure 9. Dopamine Inhibitors Image Figure 10. Global Dopamine Inhibitors Sales YoY Growth (2021-2032) & (Tons) Figure 11. Global Neurodegenerative Drugs Market Size Overview by Type (2021-2032) & (US$ Million) Figure 12. Global Neurodegenerative Drugs Market Share by Type 2025 VS 2032 Figure 13. North America Neurodegenerative Drugs Sales Market Share in Volume by Type in 2025 Figure 14. North America Neurodegenerative Drugs Sales Market Share in Value by Type in 2025 Figure 15. Europe Neurodegenerative Drugs Sales Market Share in Volume by Type in 2025 Figure 16. Europe Neurodegenerative Drugs Sales Market Share in Value by Type in 2025 Figure 17. Asia-Pacific Neurodegenerative Drugs Sales Market Share in Volume by Type in 2025 Figure 18. Asia-Pacific Neurodegenerative Drugs Sales Market Share in Value by Type in 2025 Figure 19. Latin America Neurodegenerative Drugs Sales Market Share in Volume by Type in 2025 Figure 20. Latin America Neurodegenerative Drugs Sales Market Share in Value by Type in 2025 Figure 21. Middle East and Africa Neurodegenerative Drugs Sales Market Share in Volume by Type in 2025 Figure 22. Middle East and Africa Neurodegenerative Drugs Sales Market Share in Value by Type in 2025 Figure 23. Global Top 5 and 10 Neurodegenerative Drugs Players Market Share by Revenue in 2025 Figure 24. Company Type (Tier 1, Tier 2, and Tier 3): 2021 VS 2025 Figure 25. Parkinson’s Disease Image Figure 26. Global Parkinson’s Disease Sales YoY Growth (2021-2032) & (Tons) Figure 27. Amyotrophic Lateral Sclerosis Image Figure 28. Global Amyotrophic Lateral Sclerosis Sales YoY Growth (2021-2032) & (Tons) Figure 29. Huntington Disease Image Figure 30. Global Huntington Disease Sales YoY Growth (2021-2032) & (Tons) Figure 31. Alzheimer’s Disease Image Figure 32. Global Alzheimer’s Disease Sales YoY Growth (2021-2032) & (Tons) Figure 33. Global Neurodegenerative Drugs Market Size Overview by Application (2021-2032) & (US$ Million) Figure 34. Global Neurodegenerative Drugs Market Share by Application 2025 VS 2032 Figure 35. North America Neurodegenerative Drugs Sales Market Share in Volume by Application in 2025 Figure 36. North America Neurodegenerative Drugs Sales Market Share in Value by Application in 2025 Figure 37. Europe Neurodegenerative Drugs Sales Market Share in Volume by Application in 2025 Figure 38. Europe Neurodegenerative Drugs Sales Market Share in Value by Application in 2025 Figure 39. Asia-Pacific Neurodegenerative Drugs Sales Market Share in Volume by Application in 2025 Figure 40. Asia-Pacific Neurodegenerative Drugs Sales Market Share in Value by Application in 2025 Figure 41. Latin America Neurodegenerative Drugs Sales Market Share in Volume by Application in 2025 Figure 42. Latin America Neurodegenerative Drugs Sales Market Share in Value by Application in 2025 Figure 43. Middle East and Africa Neurodegenerative Drugs Sales Market Share in Volume by Application in 2025 Figure 44. Middle East and Africa Neurodegenerative Drugs Sales Market Share in Value by Application in 2025 Figure 45. North America Neurodegenerative Drugs Sales by Country: 2021 VS 2025 VS 2032 (Tons) Figure 46. North America Neurodegenerative Drugs Sales Share by Country: 2021 VS 2025 VS 2032 Figure 47. North America Neurodegenerative Drugs Market Size by Country: 2021 VS 2025 VS 2032 (US$ Million) Figure 48. North America Neurodegenerative Drugs Market Share by Country: 2021 VS 2025 VS 2032 Figure 49. Europe Neurodegenerative Drugs Sales by Country: 2021 VS 2025 VS 2032 (Tons) Figure 50. Europe Neurodegenerative Drugs Sales Share by Country: 2021 VS 2025 VS 2032 Figure 51. Europe Neurodegenerative Drugs Market Size by Country: 2021 VS 2025 VS 2032 (US$ Million) Figure 52. Europe Neurodegenerative Drugs Market Share by Country: 2021 VS 2025 VS 2032 Figure 53. Asia-Pacific Neurodegenerative Drugs Sales by Country: 2021 VS 2025 VS 2032 (Tons) Figure 54. Asia-Pacific Neurodegenerative Drugs Sales Share by Country: 2021 VS 2025 VS 2032 Figure 55. Asia-Pacific Neurodegenerative Drugs Market Size by Country: 2021 VS 2025 VS 2032 (US$ Million) Figure 56. Asia-Pacific Neurodegenerative Drugs Market Share by Country: 2021 VS 2025 VS 2032 Figure 57. Latin America Neurodegenerative Drugs Sales by Country: 2021 VS 2025 VS 2032 (Tons) Figure 58. Latin America Neurodegenerative Drugs Sales Share by Country: 2021 VS 2025 VS 2032 Figure 59. Latin America Neurodegenerative Drugs Market Size by Country: 2021 VS 2025 VS 2032 (US$ Million) Figure 60. Latin America Neurodegenerative Drugs Market Share by Country: 2021 VS 2025 VS 2032 Figure 61. Middle East and Africa Neurodegenerative Drugs Sales by Country: 2021 VS 2025 VS 2032 (Tons) Figure 62. Middle East and Africa Neurodegenerative Drugs Sales Share by Country: 2021 VS 2025 VS 2032 Figure 63. Middle East and Africa Neurodegenerative Drugs Market Size by Country: 2021 VS 2025 VS 2032 (US$ Million) Figure 64. Middle East and Africa Neurodegenerative Drugs Market Share by Country: 2021 VS 2025 VS 2032 Figure 65. Neurodegenerative Drugs Value Chain Figure 66. Key Raw Materials Price Figure 67. Manufacturing Cost Structure Figure 68. Neurodegenerative Drugs Production Mode & Process Figure 69. Direct Comparison with Distribution Share Figure 70. Distributors Profiles Figure 71. Years Considered Figure 72. Research Process Figure 73. Key Executives Interviewed

Scope & coverage.

Types
  • NMDA
  • SSRIs
  • Dopamine Inhibitors
Applications
  • Parkinson’s Disease
  • Amyotrophic Lateral Sclerosis
  • Huntington Disease
  • Alzheimer’s Disease
Companies covered
  • TEVA
  • Sanofi
  • Novartis
  • Luye Pharma
  • Livzon Pharmaceutical
  • Kanghong Pharmaceutical
  • Jingxin Pharmaceutical
  • Pfizer
  • Huahai Pharmaceutical
  • Hisun Pharmaceutical
  • Haisco Pharmaceutical
  • GlaxoSmithKline
  • Ark Pharmaceutical
  • Dongcheng Biochemicals
  • BORA PHARMACEUTICALS
  • UCB
  • Merck Serono
  • Boehringer Ingelheim
  • Biogen Idec

Inside the report.

1 Market Overview
  1. 1.1 Product Definition
  2. 1.2 Global Market Growth Prospects
  3. 1.2.1 Global Neurodegenerative Drugs Market Size Estimates and Forecasts (2021-2032)
  4. 1.2.2 Global Neurodegenerative Drugs Sales Estimates and Forecasts (2021-2032)
  5. 1.3 Neurodegenerative Drugs Market by Type
  6. 1.3.1 NMDA
  7. 1.3.2 SSRIs
  8. 1.3.3 Dopamine Inhibitors
  9. 1.4 Global Neurodegenerative Drugs Market Size by Type
  10. 1.4.1 Global Neurodegenerative Drugs Market Size Overview by Type (2021-2032)
  11. 1.4.2 Global Neurodegenerative Drugs Historic Market Size Review by Type (2021-2026)
  12. 1.4.3 Global Neurodegenerative Drugs Forecasted Market Size by Type (2027-2032)
  13. 1.5 Key Regions Market Size by Type
  14. 1.5.1 North America Neurodegenerative Drugs Sales Breakdown by Type (2021-2026)
  15. 1.5.2 Europe Neurodegenerative Drugs Sales Breakdown by Type (2021-2026)
  16. 1.5.3 Asia-Pacific Neurodegenerative Drugs Sales Breakdown by Type (2021-2026)
  17. 1.5.4 South America Neurodegenerative Drugs Sales Breakdown by Type (2021-2026)
  18. 1.5.5 Middle East and Africa Neurodegenerative Drugs Sales Breakdown by Type (2021-2026)
2 Global Market Dynamics
  1. 2.1 Neurodegenerative Drugs Industry Trends
  2. 2.2 Neurodegenerative Drugs Industry Drivers
  3. 2.3 Neurodegenerative Drugs Industry Opportunities and Challenges
  4. 2.4 Neurodegenerative Drugs Industry Restraints
3 Market Competitive Landscape by Company
  1. 3.1 Global Top Players by Neurodegenerative Drugs Revenue (2021-2026)
  2. 3.2 Global Top Players by Neurodegenerative Drugs Sales (2021-2026)
  3. 3.3 Global Top Players by Neurodegenerative Drugs Price (2021-2026)
  4. 3.4 Global Neurodegenerative Drugs Industry Company Ranking, 2024 VS 2025 VS 2026
  5. 3.5 Global Neurodegenerative Drugs Major Company Production Sites & Headquarters
  6. 3.6 Global Neurodegenerative Drugs Company, Product Type & Application
  7. 3.7 Global Neurodegenerative Drugs Company Establishment Date
  8. 3.8 Market Competitive Analysis
  9. 3.8.1 Global Neurodegenerative Drugs Market CR5 and HHI
  10. 3.8.2 Global Top 5 and 10 Neurodegenerative Drugs Players Market Share by Revenue in 2025
  11. 3.8.3 2025 Neurodegenerative Drugs Tier 1, Tier 2, and Tier 3
4 Neurodegenerative Drugs Regional Status and Outlook
  1. 4.1 Global Neurodegenerative Drugs Market Size and CAGR by Region: 2021 VS 2025 VS 2032
  2. 4.2 Global Neurodegenerative Drugs Historic Market Size by Region
  3. 4.2.1 Global Neurodegenerative Drugs Sales in Volume by Region (2021-2026)
  4. 4.2.2 Global Neurodegenerative Drugs Sales in Value by Region (2021-2026)
  5. 4.2.3 Global Neurodegenerative Drugs Sales (Volume & Value), Price and Gross Margin (2021-2026)
  6. 4.3 Global Neurodegenerative Drugs Forecasted Market Size by Region
  7. 4.3.1 Global Neurodegenerative Drugs Sales in Volume by Region (2027-2032)
  8. 4.3.2 Global Neurodegenerative Drugs Sales in Value by Region (2027-2032)
  9. 4.3.3 Global Neurodegenerative Drugs Sales (Volume & Value), Price and Gross Margin (2027-2032)
5 Neurodegenerative Drugs by Application
  1. 5.1 Neurodegenerative Drugs Market by Application
  2. 5.1.1 Parkinson’s Disease
  3. 5.1.2 Amyotrophic Lateral Sclerosis
  4. 5.1.3 Huntington Disease
  5. 5.1.4 Alzheimer’s Disease
  6. 5.2 Global Neurodegenerative Drugs Market Size by Application
  7. 5.2.1 Global Neurodegenerative Drugs Market Size Overview by Application (2021-2032)
  8. 5.2.2 Global Neurodegenerative Drugs Historic Market Size Review by Application (2021-2026)
  9. 5.2.3 Global Neurodegenerative Drugs Forecasted Market Size by Application (2027-2032)
  10. 5.3 Key Regions Market Size by Application
  11. 5.3.1 North America Neurodegenerative Drugs Sales Breakdown by Application (2021-2026)
  12. 5.3.2 Europe Neurodegenerative Drugs Sales Breakdown by Application (2021-2026)
  13. 5.3.3 Asia-Pacific Neurodegenerative Drugs Sales Breakdown by Application (2021-2026)
  14. 5.3.4 South America Neurodegenerative Drugs Sales Breakdown by Application (2021-2026)
  15. 5.3.5 Middle East and Africa Neurodegenerative Drugs Sales Breakdown by Application (2021-2026)
6 Company Profiles
  1. 6.1 TEVA
  2. 6.1.1 TEVA Company Information
  3. 6.1.2 TEVA Business Overview
  4. 6.1.3 TEVA Neurodegenerative Drugs Sales, Revenue and Gross Margin (2021-2026)
  5. 6.1.4 TEVA Neurodegenerative Drugs Product Portfolio
  6. 6.1.5 TEVA Recent Developments
  7. 6.2 Sanofi
  8. 6.2.1 Sanofi Company Information
  9. 6.2.2 Sanofi Business Overview
  10. 6.2.3 Sanofi Neurodegenerative Drugs Sales, Revenue and Gross Margin (2021-2026)
  11. 6.2.4 Sanofi Neurodegenerative Drugs Product Portfolio
  12. 6.2.5 Sanofi Recent Developments
  13. 6.3 Novartis
  14. 6.3.1 Novartis Company Information
  15. 6.3.2 Novartis Business Overview
  16. 6.3.3 Novartis Neurodegenerative Drugs Sales, Revenue and Gross Margin (2021-2026)
  17. 6.3.4 Novartis Neurodegenerative Drugs Product Portfolio
  18. 6.3.5 Novartis Recent Developments
  19. 6.4 Luye Pharma
  20. 6.4.1 Luye Pharma Company Information
  21. 6.4.2 Luye Pharma Business Overview
  22. 6.4.3 Luye Pharma Neurodegenerative Drugs Sales, Revenue and Gross Margin (2021-2026)
  23. 6.4.4 Luye Pharma Neurodegenerative Drugs Product Portfolio
  24. 6.4.5 Luye Pharma Recent Developments
  25. 6.5 Livzon Pharmaceutical
  26. 6.5.1 Livzon Pharmaceutical Company Information
  27. 6.5.2 Livzon Pharmaceutical Business Overview
  28. 6.5.3 Livzon Pharmaceutical Neurodegenerative Drugs Sales, Revenue and Gross Margin (2021-2026)
  29. 6.5.4 Livzon Pharmaceutical Neurodegenerative Drugs Product Portfolio
  30. 6.5.5 Livzon Pharmaceutical Recent Developments
  31. 6.6 Kanghong Pharmaceutical
  32. 6.6.1 Kanghong Pharmaceutical Company Information
  33. 6.6.2 Kanghong Pharmaceutical Business Overview
  34. 6.6.3 Kanghong Pharmaceutical Neurodegenerative Drugs Sales, Revenue and Gross Margin (2021-2026)
  35. 6.6.4 Kanghong Pharmaceutical Neurodegenerative Drugs Product Portfolio
  36. 6.6.5 Kanghong Pharmaceutical Recent Developments
  37. 6.7 Jingxin Pharmaceutical
  38. 6.7.1 Jingxin Pharmaceutical Company Information
  39. 6.7.2 Jingxin Pharmaceutical Business Overview
  40. 6.7.3 Jingxin Pharmaceutical Neurodegenerative Drugs Sales, Revenue and Gross Margin (2021-2026)
  41. 6.7.4 Jingxin Pharmaceutical Neurodegenerative Drugs Product Portfolio
  42. 6.7.5 Jingxin Pharmaceutical Recent Developments
  43. 6.8 Pfizer
  44. 6.8.1 Pfizer Company Information
  45. 6.8.2 Pfizer Business Overview
  46. 6.8.3 Pfizer Neurodegenerative Drugs Sales, Revenue and Gross Margin (2021-2026)
  47. 6.8.4 Pfizer Neurodegenerative Drugs Product Portfolio
  48. 6.8.5 Pfizer Recent Developments
  49. 6.9 Huahai Pharmaceutical
  50. 6.9.1 Huahai Pharmaceutical Company Information
  51. 6.9.2 Huahai Pharmaceutical Business Overview
  52. 6.9.3 Huahai Pharmaceutical Neurodegenerative Drugs Sales, Revenue and Gross Margin (2021-2026)
  53. 6.9.4 Huahai Pharmaceutical Neurodegenerative Drugs Product Portfolio
  54. 6.9.5 Huahai Pharmaceutical Recent Developments
  55. 6.10 Hisun Pharmaceutical
  56. 6.10.1 Hisun Pharmaceutical Company Information
  57. 6.10.2 Hisun Pharmaceutical Business Overview
  58. 6.10.3 Hisun Pharmaceutical Neurodegenerative Drugs Sales, Revenue and Gross Margin (2021-2026)
  59. 6.10.4 Hisun Pharmaceutical Neurodegenerative Drugs Product Portfolio
  60. 6.10.5 Hisun Pharmaceutical Recent Developments
  61. 6.11 Haisco Pharmaceutical
  62. 6.11.1 Haisco Pharmaceutical Company Information
  63. 6.11.2 Haisco Pharmaceutical Business Overview
  64. 6.11.3 Haisco Pharmaceutical Neurodegenerative Drugs Sales, Revenue and Gross Margin (2021-2026)
  65. 6.11.4 Haisco Pharmaceutical Neurodegenerative Drugs Product Portfolio
  66. 6.11.5 Haisco Pharmaceutical Recent Developments
  67. 6.12 GlaxoSmithKline
  68. 6.12.1 GlaxoSmithKline Company Information
  69. 6.12.2 GlaxoSmithKline Business Overview
  70. 6.12.3 GlaxoSmithKline Neurodegenerative Drugs Sales, Revenue and Gross Margin (2021-2026)
  71. 6.12.4 GlaxoSmithKline Neurodegenerative Drugs Product Portfolio
  72. 6.12.5 GlaxoSmithKline Recent Developments
  73. 6.13 Ark Pharmaceutical
  74. 6.13.1 Ark Pharmaceutical Company Information
  75. 6.13.2 Ark Pharmaceutical Business Overview
  76. 6.13.3 Ark Pharmaceutical Neurodegenerative Drugs Sales, Revenue and Gross Margin (2021-2026)
  77. 6.13.4 Ark Pharmaceutical Neurodegenerative Drugs Product Portfolio
  78. 6.13.5 Ark Pharmaceutical Recent Developments
  79. 6.14 Dongcheng Biochemicals
  80. 6.14.1 Dongcheng Biochemicals Company Information
  81. 6.14.2 Dongcheng Biochemicals Business Overview
  82. 6.14.3 Dongcheng Biochemicals Neurodegenerative Drugs Sales, Revenue and Gross Margin (2021-2026)
  83. 6.14.4 Dongcheng Biochemicals Neurodegenerative Drugs Product Portfolio
  84. 6.14.5 Dongcheng Biochemicals Recent Developments
  85. 6.15 BORA PHARMACEUTICALS
  86. 6.15.1 BORA PHARMACEUTICALS Company Information
  87. 6.15.2 BORA PHARMACEUTICALS Business Overview
  88. 6.15.3 BORA PHARMACEUTICALS Neurodegenerative Drugs Sales, Revenue and Gross Margin (2021-2026)
  89. 6.15.4 BORA PHARMACEUTICALS Neurodegenerative Drugs Product Portfolio
  90. 6.15.5 BORA PHARMACEUTICALS Recent Developments
  91. 6.16 UCB
  92. 6.16.1 UCB Company Information
  93. 6.16.2 UCB Business Overview
  94. 6.16.3 UCB Neurodegenerative Drugs Sales, Revenue and Gross Margin (2021-2026)
  95. 6.16.4 UCB Neurodegenerative Drugs Product Portfolio
  96. 6.16.5 UCB Recent Developments
  97. 6.17 Merck Serono
  98. 6.17.1 Merck Serono Company Information
  99. 6.17.2 Merck Serono Business Overview
  100. 6.17.3 Merck Serono Neurodegenerative Drugs Sales, Revenue and Gross Margin (2021-2026)
  101. 6.17.4 Merck Serono Neurodegenerative Drugs Product Portfolio
  102. 6.17.5 Merck Serono Recent Developments
  103. 6.18 Boehringer Ingelheim
  104. 6.18.1 Boehringer Ingelheim Company Information
  105. 6.18.2 Boehringer Ingelheim Business Overview
  106. 6.18.3 Boehringer Ingelheim Neurodegenerative Drugs Sales, Revenue and Gross Margin (2021-2026)
  107. 6.18.4 Boehringer Ingelheim Neurodegenerative Drugs Product Portfolio
  108. 6.18.5 Boehringer Ingelheim Recent Developments
  109. 6.19 Biogen Idec
  110. 6.19.1 Biogen Idec Company Information
  111. 6.19.2 Biogen Idec Business Overview
  112. 6.19.3 Biogen Idec Neurodegenerative Drugs Sales, Revenue and Gross Margin (2021-2026)
  113. 6.19.4 Biogen Idec Neurodegenerative Drugs Product Portfolio
  114. 6.19.5 Biogen Idec Recent Developments
7 North America by Country
  1. 7.1 North America Neurodegenerative Drugs Sales by Country
  2. 7.1.1 North America Neurodegenerative Drugs Sales Growth Rate (CAGR) by Country: 2021 VS 2025 VS 2032
  3. 7.1.2 North America Neurodegenerative Drugs Sales by Country (2021-2026)
  4. 7.1.3 North America Neurodegenerative Drugs Sales Forecast by Country (2027-2032)
  5. 7.2 North America Neurodegenerative Drugs Market Size by Country
  6. 7.2.1 North America Neurodegenerative Drugs Market Size Growth Rate (CAGR) by Country: 2021 VS 2025 VS 2032
  7. 7.2.2 North America Neurodegenerative Drugs Market Size by Country (2021-2026)
  8. 7.2.3 North America Neurodegenerative Drugs Market Size Forecast by Country (2027-2032)
8 Europe by Country
  1. 8.1 Europe Neurodegenerative Drugs Sales by Country
  2. 8.1.1 Europe Neurodegenerative Drugs Sales Growth Rate (CAGR) by Country: 2021 VS 2025 VS 2032
  3. 8.1.2 Europe Neurodegenerative Drugs Sales by Country (2021-2026)
  4. 8.1.3 Europe Neurodegenerative Drugs Sales Forecast by Country (2027-2032)
  5. 8.2 Europe Neurodegenerative Drugs Market Size by Country
  6. 8.2.1 Europe Neurodegenerative Drugs Market Size Growth Rate (CAGR) by Country: 2021 VS 2025 VS 2032
  7. 8.2.2 Europe Neurodegenerative Drugs Market Size by Country (2021-2026)
  8. 8.2.3 Europe Neurodegenerative Drugs Market Size Forecast by Country (2027-2032)
9 Asia-Pacific by Country
  1. 9.1 Asia-Pacific Neurodegenerative Drugs Sales by Country
  2. 9.1.1 Asia-Pacific Neurodegenerative Drugs Sales Growth Rate (CAGR) by Country: 2021 VS 2025 VS 2032
  3. 9.1.2 Asia-Pacific Neurodegenerative Drugs Sales by Country (2021-2026)
  4. 9.1.3 Asia-Pacific Neurodegenerative Drugs Sales Forecast by Country (2027-2032)
  5. 9.2 Asia-Pacific Neurodegenerative Drugs Market Size by Country
  6. 9.2.1 Asia-Pacific Neurodegenerative Drugs Market Size Growth Rate (CAGR) by Country: 2021 VS 2025 VS 2032
  7. 9.2.2 Asia-Pacific Neurodegenerative Drugs Market Size by Country (2021-2026)
  8. 9.2.3 Asia-Pacific Neurodegenerative Drugs Market Size Forecast by Country (2027-2032)
10 South America by Country
  1. 10.1 South America Neurodegenerative Drugs Sales by Country
  2. 10.1.1 South America Neurodegenerative Drugs Sales Growth Rate (CAGR) by Country: 2021 VS 2025 VS 2032
  3. 10.1.2 South America Neurodegenerative Drugs Sales by Country (2021-2026)
  4. 10.1.3 South America Neurodegenerative Drugs Sales Forecast by Country (2027-2032)
  5. 10.2 South America Neurodegenerative Drugs Market Size by Country
  6. 10.2.1 South America Neurodegenerative Drugs Market Size Growth Rate (CAGR) by Country: 2021 VS 2025 VS 2032
  7. 10.2.2 South America Neurodegenerative Drugs Market Size by Country (2021-2026)
  8. 10.2.3 South America Neurodegenerative Drugs Market Size Forecast by Country (2027-2032)
11 Middle East and Africa by Country
  1. 11.1 Middle East and Africa Neurodegenerative Drugs Sales by Country
  2. 11.1.1 Middle East and Africa Neurodegenerative Drugs Sales Growth Rate (CAGR) by Country: 2021 VS 2025 VS 2032
  3. 11.1.2 Middle East and Africa Neurodegenerative Drugs Sales by Country (2021-2026)
  4. 11.1.3 Middle East and Africa Neurodegenerative Drugs Sales Forecast by Country (2027-2032)
  5. 11.2 Middle East and Africa Neurodegenerative Drugs Market Size by Country
  6. 11.2.1 Middle East and Africa Neurodegenerative Drugs Market Size Growth Rate (CAGR) by Country: 2021 VS 2025 VS 2032
  7. 11.2.2 Middle East and Africa Neurodegenerative Drugs Market Size by Country (2021-2026)
  8. 11.2.3 Middle East and Africa Neurodegenerative Drugs Market Size Forecast by Country (2027-2032)
12 Value Chain and Sales Channels Analysis
  1. 12.1 Neurodegenerative Drugs Value Chain Analysis
  2. 12.1.1 Neurodegenerative Drugs Key Raw Materials
  3. 12.1.2 Key Raw Materials Price
  4. 12.1.3 Raw Materials Key Suppliers
  5. 12.1.4 Manufacturing Cost Structure
  6. 12.1.5 Neurodegenerative Drugs Production Mode & Process
  7. 12.2 Neurodegenerative Drugs Sales Channels Analysis
  8. 12.2.1 Direct Comparison with Distribution Share
  9. 12.2.2 Neurodegenerative Drugs Distributors
  10. 12.2.3 Neurodegenerative Drugs Customers
13 Concluding Insights
    14 Appendix
    1. 14.1 Reasons for Doing This Study
    2. 14.2 Research Methodology
    3. 14.3 Research Process
    4. 14.4 Authors List of This Report
    5. 14.5 Data Source
    6. 14.5.1 Secondary Sources
    7. 14.5.2 Primary Sources
    8. 14.6 Disclaimer

    GET THE RESEARCH

    Choose your license.

    Choose who needs access.
    All options are for this report and research series.

    Compare access permissions.

    Single User License
    One named user. Individual access.
    Multi User License
    Up to 5 users in the same department.
    Enterprise License
    Organization-wide access within the agreed license.

    Access applies to the purchased edition. Later editions are separate purchases.

    License options
    $3,450USD
    Buy now

    PDF by email within 3–5 working days after payment confirmation.

    Talk to an analyst
    APO Research
    Talk to an analyst